$PMCB Goldman reviews approval odds for PharmaCyte's pancreatic cancer treatment
Stock market research firm Goldman Small Cap Research has published a new sponsored research article on US clinical stage biotech firm PharmaCyte Biotech’s (OTCQB: PMCB) investigational pancreatic cancer treatment.
In the update, analyst Rob Goldman notes that major industry and company news released last week should take investor sentiment to a new level regarding the potential of Food and Drug Administration approval for PharmaCyte's pancreatic cancer treatment for patients with locally advanced pancreatic cancer.
According to Goldman: "Merrimack Pharmaceuticals [Nasdaq: MACK] was awarded FDA approval last week for its treatment designed for patients with metastatic pancreatic cancer [Onivyde (irinotecan liposome injection); The pharma Letter October 23]. Considering its poor side effect profile, associated warning label and incrementally positive median survival rate, it appears that the bar has been lowered by the FDA for priority approval of pancreatic cancer therapies which serves as a huge positive for PharmaCyte timing-wise as well. Plus, both Merrimack and PharmaCyte use an encapsulation approach to treatment, which is yet another plus in PharmaCyte's corner."
"Hall of Fame clinical research organizations and oncologists collaborated on the future PharmaCyte trial design and protocols which includes conducting the trial in the USA. Separately, these well-regarded CRO and oncology partners provide the company with unique insight and experience into what it takes to initiate and execute a pancreatic cancer therapy trial that has the best possible chance for success. Therefore, their inclusion in the trial design and management process should be viewed as a meaningful positive, noted Goldman."
Goldman continued: "In its upcoming trial, the company's treatment is being positioned as an expansion of the current gold standard of care or as a consolidation therapy, rather than a front-line therapy that goes head-to-head against the gold standard. By positioning PharmaCyte as the next or last stage therapy may be the fastest route to approval, as there is no truly effective therapy for patients at this stage that can materially extend survival rates and improve their quality of life. Moreover, as a consolidation therapy PharmaCyte plays to the strengths of the Cell-in-a-Box+ low-dose ifosfamide chemotherapy, given the very strong one-year survival rates and no side effects in its first clinical trial, and could mirror Merrimack's approval timing and sales potential, if approved."
PharmaCyte Biotech, Pancreatic cancer, Ifosfamide, Cell-in-s-Box, Approval odds, USA, FDA, Goldman Small Cap Research
